ABSTRACT

Alzheimer’s disease remains a major unmet medical need representing a huge societal burden and a difficult event in the lives of patients and families. Current treatments do not offer hope for disease altering outcomes and recent attempts to bring forward new therapies have proven largely unsuccessful. This presentation will review two programs at Bristol-Myers Squibb spanning two therapeutic targets and two drug structural classes, or modalities: Small molecules and antisense oligonucleotides (ASOs). Efforts to improve the stereospecific synthesis of an important class of ASOs will be described.